First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report

Authors

Kaiwen Wang
Ceylan Altintas Taslic
Patricia de Groot
Mitchell A Parma
Alvaro Guimaraes Paula
Melody Caranto
Komal Shah
Mukulika Bose
Cole Ruoff
Loukia G Karacosta
Lauren A Byers
Carl M Gay
Jianjun Zhang
John V Heymach
Bingnan Zhang

Language

English

Publication Date

2-1-2026

Journal

JTO Clinical and Research Reports

DOI

10.1016/j.jtocrr.2025.100941

PMID

41584719

PMCID

PMC12828416

PubMedCentral® Posted Date

12-12-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Small cell transformation has been described as a resistance mechanism to targeted therapy treated in patients with EGFR-mutated NSCLC and less often reported with those with other actionable oncogenic alterations, including ALK-rearranged NSCLC. Given lack of standard-of-care treatments for patients with actionable oncogenic alteration NSCLC transformed to SCLC, this remains a challenge and unmet need for treating these patients.

Here, we present a case of a patient with ALK-rearranged NSCLC with transformation to SCLC, who has progressed on several lines of therapies and successfully treated with tarlatamab to elicit and maintain clinical benefit, including intracranial response.

Keywords

Tarlatamab, Small cell transformation, ALK, Lorlatinib, Case report

Published Open-Access

yes

Recommended Citation

Wang, Kaiwen; Taslic, Ceylan Altintas; de Groot, Patricia; et al., "First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report" (2026). Faculty, Staff and Student Publications. 5407.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5407